Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TCRX Stock Chart & Stats
$1.10
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.10
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$1.02 - $4.94
Previous CloseN/A
Volume150.47K
Average Volume (3M)891.70K
Market Cap
$62.42M
Enterprise Value$147.47M
Total Cash (Recent Filing)$184.45M
Total Debt (Recent Filing)$95.62M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding52,471,405
10 Day Avg. Volume1,358,689
30 Day Avg. Volume891,704
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.41
Price to Sales (P/S)120.90
P/FCF Ratio-2.97
Enterprise Value/Market Cap2.36
Enterprise Value/Revenue24.94
Enterprise Value/Gross Profit24.94
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$5.50Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsUpdated data from the ALLOHA Phase 1 demonstrated a relapse of 18% in the TSC-101 cohort compared to the 36% control arm with encouraging HR trends across relapse free survival, relapse probability, event free survival, and overall survival.
Financial StabilityTscan ended with $184.5M in cash and cash equivalents, guided to support operations into the second half of 2027.
Regulatory Approval PathwayTScan announced FDA alignment on the pivotal trial design for TSC-101 in AML and MDS, reinforcing a clear regulatory path toward registration.
Bears Say
Program DeprioritizationTscan had deprioritized development of TCR-Ts in solid malignancies and enrollment in the PLEXI-T study was paused.
Study DelaysThe FDA has requested a 5 patient lead-in to assess the manufacturing process and fixed dose administration, delaying pivotal study initiation by 2 quarters.
Workforce ReductionThe company announced a workforce reduction of approximately 30%, which is intended to extend the cash runway.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $1.02 and its highest was $4.94 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $62.42M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 113 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 52,471,405 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (400.00% Upside)
$5.50 (400.00% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.17%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
-24.65%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics is a biotechnology company focused on developing innovative T cell-based therapies for the treatment of cancer and viral infections. The company specializes in harnessing the power of T cell receptors (TCRs) to create targeted therapies that aim to eliminate cancer cells while sparing healthy tissue. TScan operates primarily in the oncology sector, utilizing advanced technologies to identify and develop TCR-based treatments that address unmet medical needs in patients with difficult-to-treat malignancies.
TCRX Stock 12 Month Forecast
Average Price Target
$5.50
▲(400.00% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
20.20% Insiders
6.46% Mutual Funds
43.85% Other Institutional Investors
23.87% Public Companies and Individual Investors
Options Prices
Currently, No data available
---